0000000000267270

AUTHOR

Nathan Dwyer

0000-0002-1583-8290

showing 2 related works from this author

Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction…

2019

Background Physicians’ adherence to guideline-recommended therapy is associated with short-term clinical outcomes in heart failure (HF) with reduced ejection fraction (HFrEF). However, its impact on longer-term outcomes is poorly documented. In this analysis we assessed the longer-term association of physicians’ adherence with clinical outcomes, including mortality and unplanned hospitalisations, at 18-month follow-up of the QUALIFY registry (Clinical trial registration ISRCTN87465420) Method and results Data at 18 months were available for 6118 ambulatory HFrEF patients from this international prospective observational survey. Adherence was measured as a continuous variable, ranging from 0…

Malemedicine.medical_specialtyDoseMedication Therapy ManagementHeart failureOutcomes030204 cardiovascular system & hematologyGuidelinesMedication03 medical and health sciences0302 clinical medicineDosageInternal medicineMedication therapy managementOutcome Assessment Health CareOutpatientsmedicineHumansRegistriesPractice Patterns Physicians'Heart FailureEjection fractionGuideline adherencebusiness.industryCardiovascular AgentsStroke VolumeStroke volumeMiddle Agedmedicine.diseaseQuality ImprovementConfidence intervalClinical trialHospitalizationAdherenceHeart failureCardiovascular agentAmbulatoryPractice Guidelines as TopicObservational studyFemaleGuideline AdherenceCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesEuropean journal of heart failure
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct